This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The nation’s largest health care company pressed thousands of its clinicians to use a thinly tested medical device to screen people for artery disease, dramatically boosting payments from the federal government for years even though many of the patients were not sick, a STAT investigation found. The result was a torrent of sometimes questionable diagnoses of peripheral artery disease.
If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words: “Delivery. Delivery. Delivery.” Gene-editing technologies hold huge promise for treating hundreds, even thousands of inherited diseases.
Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.
As I hurried to an important meeting about my Ph.D. dissertation one day in 2015, I slipped and fell on Iowa’s formidable winter ice. I quickly jumped up to prevent anyone from seeing me on the ground and got into my car. The immediate, excruciating pain told me that something really bad had happened. As I drove to my meeting in tears, I called my sister.
LONDON — Patients in England with a rare blood disorder will now be able to receive the world’s first CRISPR-based medicine, after drugmaker Vertex Pharmaceuticals and U.K. health officials struck a reimbursement deal for the pricey treatment. The National Institute for Health and Care Excellence, the U.K.’s cost-effectiveness watchdog, said early Thursday that it was recommending the treatment, called Casgevy, for certain patients with beta thalassemia, a condition that oth
Purdue Pharma, the company best known for fueling the opioid crisis by misleadingly marketing the infamous painkiller OxyContin, received approval on Wednesday for a new auto-injector device used to reverse opioid overdoses. The announcement represents the latest in a string of recent approvals for products that use nalmefene, essentially a more powerful version of its better-known chemical cousin, naloxone.
Explore the innovative applications of mRNA technologies beyond COVID-19 vaccines. Learn about the potential and future developments in this groundbreaking field.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Novo Nordisk is pulling its regulatory submissions to expand the use of its obesity drug Wegovy for a common type of heart failure, saying that waiting for more data on cardiovascular outcomes could bolster its case. Trials of Wegovy in the condition, heart failure with preserved ejection fraction (or HFpEF), have primarily looked at the drug’s effects on symptoms and physical function.
Social media creator Yasir Sacranie's videos usually deal with the day-to-days of pharmacist life, alongside educational content, top tips and study guides, promoting his training platform MicroPharm. But in recent days, he's begun responding to racist and Islamophobic comments as violent unrest and intimidation has spread across parts of the UK. He sat down with The […] The post Yasir Sacranie: The TikTok pharmacist responding to online abuse appeared first on The Pharmacist.
The Centers for Medicare and Medicaid Services has finalized its rule easing reimbursement for medical device makers. Called Transitional Coverage for Emerging Technologies, the program gives device makers with products deemed “breakthrough” technology by the Food and Drug Administration a quicker way to secure Medicare coverage. The agency first introduced the rule last June.
Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.
LONDON — An underwhelming earnings report and ongoing questions about increasing competition in the booming obesity medicine field sent Novo Nordisk’s shares down early Wednesday, as the company sought to project its ability to reach more patients by increasing the supplies of its medicines. Novo shares were down about 5% after the company lowered its operating profit guidance to 20% to 28%, down from the 22% to 30% it forecasted in its last earnings report.
The U.S. Food and Drug Administration has scolded Bristol Myers Squibb for making false and misleading claims about a lung cancer treatment on a website aimed at physicians. In an Aug. 1 letter , the agency admonished the company for touting the benefits of its Krazati medication by referencing efficacy data that did not support statements on the website designed for health care providers.
Explore how artificial intelligence and machine learning are revolutionising the medical devices sector. Learn about the innovative technologies and how companies are navigating evolving regulations in this rapidly advancing field.
Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.
CVS Health continued to pay out more than it expected for the medical claims of its Medicare Advantage enrollees in the second quarter, forcing the company to lower its estimates for this year’s profits for the second straight quarter. Those higher medical costs led CVS chief executive Karen Lynch to remove Brian Kane , the president of Aetna, the subsidiary that operates all health insurance plans.
Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to treat neurodegenerative diseases. Sangamo is expected to receive $50m in near-term upfront license fees and milestone payments after granting Genentech exclusive licensing for its proprietary zinc finger repressors – that are directed to the tau […] The post Sangamo Therapeutics and Genentech team up to develop genomic medicines for
The polarized debate over drug pricing has generated cartoonish, sometimes colorful caricatures of the biopharmaceutical industry and its leaders. Critics of the industry have portrayed pharmaceutical leaders as ruthless, rapacious leaders who gouge patients to gratify greedy shareholders. While one might expect industry trade organizations to defend their leaders, their responses have sometimes portrayed leaders as powerless proxies of their shareholders whose product portfolios and profits wou
Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.
Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far, so we are determined to hang on for another couple of days. And why not? The alternatives — at least those we can identify — are not so appetizing. And what better way to make the time fly than to keep busy.
Quarterly revenue from Ozempic and Wegovy missed Wall Street estimates by about 9%, concerning some analysts and causing a stock sell-off costing the Danish drugmaker tens of billions in market value.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We recap another slew of earnings reported this morning and last night. Let’s get straight into it.
Pharmacists across primary care and community pharmacy have shared how racist and Islamophobic violence across parts of the UK in recent days have affected them and their work. The situation has left some pharmacists fearful of seeing patients and going to work, and living in what they have described as a state of 'anxiety and […] The post UK riots: ‘Pharmacists feel vulnerable and scared at work’ appeared first on The Pharmacist.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Input your email to sign up, or if you already have an account, log in here!
Enter your email address to reset your password. A temporary password will be e‑mailed to you.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content